A large number of studies have indicated that the gene encoding the p53 phosphoprotein is perhaps the most frequent target for structural and functional alterations in human cancer cells (reviewed in references 31, 41, 48, and 73) . Underlying these alterations is the fact that the wildtype (wt) p53 gene can act as a potent tumor suppressor, whose ongoing expression apparently interferes with neoplastic progression. Indeed, in a variety of transformed cell types, wt p53 has been shown to block proliferation (1, 12, 45, 47) , as well as to induce differentiation (61, 62) and programmed cell death (77) . Recent studies suggest that the tumor suppressor activity of wt p53 involves the sequencespecific binding of the protein to defined DNA targets (3, 13, 40) . This binding, which could be compatible with a regulatory role for wt p53 in processes such as transcription or DNA replication, is abolished by various mutations of the types encountered in cancer cells.
Unlike wt p53, many mutant forms of p53 actually promote neoplastic processes. Thus, mutant p53 can immortalize primary cells (34, 35, 59) , cooperate with activated ras in the transformation of such cells (14, 17, 21, 53) , and increase the tumorigenicity of established cell lines (16, 76) . In fact, the vast majority of tumor-derived p53 mutants studied thus far, of both rodent and human origin, have been found to exhibit at least some transforming activity in experimental model systems (14, 29, 30, 32) . It therefore appears most likely that, at least in some cases, p53 gene mutations contribute to cancer development not only through the elimination of a functional wt allele, but also through the generation of a transforming allele.
The mechanism responsible for the oncogenic activity of mutant p53 is still not totally clear. One very attractive possibility is that such mutants act in a dominant negative manner to abrogate the activity of coexpressed wt p53 (15, 20, 26) . Hence, one assumes that the presence of mutant p53 in cells which still retain wt p53 expression attenuates the tumor suppressor functions of the latter. This could be achieved indirectly, e.g., by competition between mutant and wt p53 for common molecular targets. However, there * Corresponding author.
are strong indications that, in the case of p53, the mutant may directly interact with the wt protein, thereby presumably rendering it inactive; this interaction entails the formation of stable complexes between the two forms of the protein (14, 20, 49, 59) . The dominant negative model for the action of mutant p53 also gains support from the fact that one usually requires a substantial excess of mutant over wt protein to elicit efficient transforming effects (see reference 48 for a detailed discussion).
It should be stressed, however, that negative dominance cannot be the only mode in which mutant p53 exerts its transforming effects. This was most clearly borne out by studies in which the introduction of mutant p53 could enhance the tumorigenicity of cells not expressing any endogenous p53 at all (6, 64, 76) . It is noteworthy that such positive dominant action of mutant p53 became much more pronounced when analyzed in animals rather than in cultured cells. Data compatible with at least some direct oncogenic activity of certain p53 mutants was also obtained from the comparative study of tumor-derived rodent and human p53 mutants (29, 32) .
In an attempt to gain further insight into the molecular basis underlying p53-mediated transformation, we analyzed the transforming potential of short p53 fragments. We report here that the C-terminal domain of p53 can act as a potent transforming protein, with efficiencies similar to those exhibited by tumor-derived full-length mutant p53. (17) .
Immunoprecipitation and protein analysis. Cells were labeled with [35S]methionine, and extracts were prepared as described previously (43) . Equal amounts of trichloroacetic acid-insoluble radioactivity were subjected to immunoprecipitation with various p53-specific antibodies, as described earlier (47) . Immunoprecipitated proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 12.5% gels. Gels were fluorographed with 2,5-diphenyloxazole-dimethyl sulfoxide, dried, and exposed to Agfa Curix X-ray film.
For Western blotting (immunoblotting), extract portions containing equal amounts of total nonradioactive protein were subjected to SDS-PAGE on a 12.5% polyacrylamide gel, transferred onto nitrocellulose membranes (Schleicher & Schuell), and incubated for 1 h at room temperature with blocking solution (10% low-fat milk, 0.05% Tween 20 in phosphate-buffered saline). PAb421 hybridoma supernatant (diluted 1:30) was used as a probe and was followed by goat anti-mouse horseradish peroxidase-conjugated antibodies (diluted 1:20,000). Chemiluminescent signals were generated by incubation with the ECL reagents (Amersham, United Kingdom) according to the manufacturer's instructions.
To obtain quantitative data from autoradiograms, we scanned the respective bands in a computing densitometer (model 300A; Molecular Dynamics).
In vitro transcription and translation. RNA was synthesized from the SP6-based in vitro transcription plasmids by using SP6 RNA polymerase (Promega) according to the manufacturer's instructions. The resultant transcripts were translated in a nuclease-treated rabbit reticulocyte lysate (Promega) according to the manufacturer's instructions. In vitro-translated polypeptides were processed for immunoprecipitation or DNA binding assays immediately after completion of the translation reaction.
Immunofluorescence. Indirect immunofluorescence with monoclonal antibody PAb421 was used to visualize p53 as described previously (25) .
DNA binding. Sequence-specific DNA binding assays were performed essentially as described by Kern et al. (40) , with certain modifications. Cell extracts were made as described earlier (43) , and total protein concentration was estimated from the optical density reading at 280 nm. In some experiments, a double-stranded DNA target site for sequence-specific p53 binding (40) 
RESULTS
Oligomerization potential of C-terminal p53 faments. The notion that oncogenic p53 mutants transform through a dominant negative mechanism is, to a great extent, based on the finding that such mutants form stable complexes with the endogenous p53 in transformed cells (14, 59) . In an attempt to determine whether the ability to form such complexes is indeed essential for transformation, we generated short versions of p53 (miniproteins) carrying various segments of the C-terminal region. It is noteworthy that these miniproteins are derived from wt p53 and, aside from being severely truncated, carry no mutations, as confirmed by DNA sequence analysis (data not shown). The rationale for this approach was based on the earlier demonstration that truncation of the C-terminal end of the protein abolished its oligomerization potential (36, 49) . This suggested that the putative oligomerization domain of p53 resides near its C-terminal end.
In the first three expression plasmids (Fig. 1 , pCMVDD, pCMVDt360, and pCMVDASS), a short stretch of N-terminal residues was included in front of the various C-terminal segments. On the basis of the open reading frame of mouse p53 mRNA (78) , this N-terminal stretch is expected to encode the first 14 residues of p53. However, the analysis of p53 cDNA from a variety of vertebrate species (67) now strongly indicates that the second in-frame AUG of mouse p53 RNA (formally codon 4) may in fact represent the correct translation initiation site. Hence, these expression plasmids probably encode only the first 11 residues of authentic mouse p53. In addition to this short N-terminal stretch, pCMVDD encodes residues 302 to 390 of mouse p53 (numbering as in reference 78). pCMVDt360 encodes a truncated miniprotein terminating at residue 360. pCMVD ASS is a derivative of pCMVDD containing an in-frame deletion that removes residues 330 to 344.
It appears rather unlikely that the short N-terminal stretch of p53 encoded by these plasmids possesses any distinct transforming activity. In fact, the comparable region of human p53 fails to exhibit any transcriptional activation potential (70) , the only activity mapped so far to the N terminus of p53. Nevertheless, to exclude unequivocally the possibility that this element was responsible for effects monitored in subsequent experiments, we constructed an additional expression vector ( Fig. 1, pCMVN315 ). The miniprotein encoded by this vector is expected to contain only one, or at most four, N-terminal residues of p53, fused directly to amino acid 315 of the normal protein. It is noteworthy that these miniproteins should also include all three nuclear localization signals of p53 (62) , with the exception of the polypeptide encoded by pCMVDt360; the latter should contain only NLS I, the major nuclear localization signal.
Each of the above miniproteins was next tested for its ability to associate with full-length wt p53. The latter was chosen as the oligomerization partner since it has been proposed to lose its tumor suppressor activity when complexed with biochemically impaired mutant p53 (15, 20, 26, 49) . In vitro transcription vectors, using the SP6 promoter, were constructed from each of the expression plasmids shown in Fig. 1 ; this yielded plasmids pSPDD, pSPDt360, pSPDASS, and pSPN315, respectively. After transcription, each miniprotein RNA was translated in a rabbit reticulocyte lysate, either alone or together with RNA encoding wt mouse p53. It has been reported previously that cotranslation was necessary to allow the formation of mixed p53 oligomers (49, 50). The translated proteins were then subjected to immunoprecipitation with various antibodies. The antibodies used included the p53-specific monoclonal antibodies PAb421 and RA3.2C2, as well as a p53-specific rabbit polyclonal serum. The PAb421 epitope is located near the C-terminal end of p53 (71) and thus should react directly with the miniproteins encoded by pSPDD, pSPDASS, and pSPN315. The product of pSPDt360 will not contain the PAb421 epitope, and thus we had to use the polyclonal serum to bring it down directly. On the other hand, none of these miniproteins will bind to RA3.2C2, whose cognate epitope is located in the central region of p53 (between residues 157 and 192, [71] ). The only way that such a miniprotein can be precipitated by RA3.2C2 is through formation of a complex with cotranslated wt p53. Hence, the presence of a given miniprotein in an RA3.2C2 immunoprecipitate from a cotranslation will imply that this miniprotein can still oligomerize with full-length wt p53.
The results of such an experiment are displayed in Fig. 2 . It is noteworthy that all miniproteins had a higher apparent molecular size than predicted from their amino acid composition ( Fig . On the other hand, when RA3.2C2 was reacted with products of cotranslation reactions, a fraction of the miniproteins encoded by either pSPDD or pSPDt360 did precipitate in the presence of the full-length protein ( Fig. 2A, lanes 12 and 14) . A similar behavior was exhibited also by the pSPN315 product (Fig.  2B, lane 2) . Hence, all these three miniproteins still possess the ability to oligomerize with cotranslated wt p53. By contrast, the DASS miniprotein did not exhibit any detectable coprecipitation with wt p53 (Fig. 2A, lane 13 Half of each translation reaction was precipitated with PAb421 (421; lanes 1, 2, and 4 to 6) or with a p53-specific rabbit polyclonal serum (P.C.; lanes 3 and 7), both of which recognize the C-terminal fragments as well as the intact wt p53 (see text). The other half was reacted with the monoclonal antibody RA3.2C2 (2C2; lanes 8 and 14), which can bind directly only to full-length p53 made in these reactions. The translation reactions were as follows: lanes 1 and 8, DD; lanes 2 and 9, DASS; lanes 3 and 10, Dt360; lanes 4 and 11, wt p53; lanes 5 The results of a series of such transfection experiments are summarized in Table 1 . As expected, cotransfection with ras plus the control plasmid pCMVp53dl gave rise only to very rare foci, which could not be expanded into established lines. On the other hand, cotransfection of ras with pDM VDD, pCMVDt360, or pCMVN315 reproducibly gave rise to numerous continuously growing foci, which could be expanded efficiently into established cell lines. In contrast, pCMVDASS, encoding an oligomerization-deficient polypeptide, failed to cooperate with ras in transformation and did not increase the number of foci above background. Interestingly, in these experiments, the plasmids encoding the transforming miniproteins were even more effective than pCMVp53m, encoding full-length mutant p53 under the same promoter. In fact, the former were as transforming in this assay as pLTRcGvall35, which is a most potent transformer (14, 31) . To assess the relationship between the transforming activities of C-terminal fragments and of full-length mutant p53, we next examined the effect of pCMVDD on the transformation induced by ras plus pLTRcGvall35. As seen in Table  1 (bottom row), pCMVDD did not increase the efficiency of transformation by full-length mutant p53. Hence, both plasmids seem to transform the same target cell population, suggesting that both may be operating through a common mechanism.
Another manifestation of the oncogenic potential of mutant p53 is its ability to enhance transformation by other oncogene combinations, such as adenovirus Ela plus ras (15, 20) , myc plus ras (15) , or human papillomavirus E6 plus ras (9) . We therefore tested whether this effect, too, could be exerted by the C-terminal miniproteins. As seen in Table 2 , this was indeed the case. While addition of pDMVDD, pCMVDt360, or pCMVN315 to a mixture of ras and myc expression plasmids increased focus formation severalfold, pCMVDASS had absolutely no enhancing effect. Neither did pCMVDASS exhibit any ability to suppress oncogene-mediated transformation, unlike full-length wt p53. As before, the plasmids encoding the miniproteins were more effective than pCMVp53m, encoding full-length mutant p53. (Fig. 3) .
In all four types of cell lines, there was a pronounced expression of low-molecular-weight polypeptides of the same size as obtained by in vitro translation. Unlike in the latter system, the proteins made in vivo (with the exception of N315) typically migrated as doublets, perhaps reflecting some sort of posttranslational modification (serine 312 phosphorylation?). As seen in Fig. 3D , expression of the DASS miniprotein was also observed in seven of eight lines. Hence, the failure of pCMVDASS to transform does not stem from an inability to direct the synthesis of the corresponding protein, but rather would appear to represent an intrinsic property of this internally deleted polypeptide. Unlike the lines shown in Fig. 3A tended to lose expression rapidly upon passaging in culture (see Fig. 8 ). This further indicates that the continuous expression of the nontransforming C-terminal fragment of p53 confers no selective growth advantage, and may actually even be selected against.
Cell lines obtained from dishes doubly transfected with ras and pCMVDD, pCMVDt360, or pCMVN315 (without myc) also made substantial amounts of the corresponding miniproteins (data not shown). As pCMVDASS did not cooperate with ras in the transformation of REF (Table 1) , no pertinent cell lines could be generated.
Nuclear localization of C-terminal miniproteins. In cells expressing a ts p53 mutant, the intracellular localization of the protein correlates with its state of activity (23, 25, 44) . Thus, when the ts p53 is in the mutant, nonsuppressor conformation, it is predominantly found in the cytoplasm. On the other hand, when the ts p53 is converted into a wt-like conformation, leading to induction of antiproliferative activities, it becomes primarily nuclear. These findings are compatible with a model in which mutant p53 acts in a dominant negative manner by sequestering associated endogenous wt p53 in the cytoplasm at a point in the cell cycle when it should act in the nucleus (44) . The C-terminal miniproteins appear to act in a manner similar to that of full-length mutant p53. It was therefore of interest to determine whether in their case, too, transforming activity was associated with cytoplasmic accumulation. To that end, the subcellular localization of the transformation-competent DD miniprotein was compared with that of the nontransforming DASS polypeptide.
RMDD and RMDASS cells were plated at low density, fixed, and subjected to immunofluorescent staining with PAb421 (Fig. 4) . In general, p53 miniprotein levels were significantly higher in RMDD lines, resulting in a better signal-to-noise ratio. This was reflected in the need for longer photographic exposure times with RMDASS cells (see the legend to Fig. 4 ). These differences most probably stem from a gradual loss of DASS protein expression during passaging in culture, as discussed earlier. Notwithstanding the quantitative differences between the two types of cells, the corresponding miniproteins were found concentrated in the cell nucleus in both cases. On the other hand, cells transformed by myc plus ras without any additional p53 plasmid yielded only diffuse background staining (Fig. 4d) . Moreover, practically the entire population of miniproteinexpressing cells exhibited a nuclear localization of the p53 staining. Hence, unlike the case for certain full-length p53 mutants, transforming potential was not correlated with exclusion of much of the protein from the nucleus.
It is of note that virtually the entire population of DDexpressing cells displayed an unequivocal nuclear presence of this miniprotein. This is unlike the observation made for full-length wt p53, which seems to oscillate between cytoplasm and nucleus in a cell cycle-dependent manner (64) . In its cytoplasmic phase, p53 may be actively prevented from entering the nucleus by virtue of its association with a putative cytoplasmic anchor (23) . In such case, our findings would imply that interaction with that anchor requires elements of p53 located outside the region included in the DD miniprotein.
Transformation potential of C-terminal miniproteins correlates with inhibition of the DNA binding activity of endogenous p53. wt p53 can bind specific DNA sequences, whereas tumor-derived mutants of p53 are greatly impaired in their ability to do so (3, 13, 40 Such binding will presumably be abortive, as these miniproteins most probably lack other domains of the protein needed for normal biochemical activity. Nevertheless, it will prevent the much less abundant endogenous p53 molecules from interacting with these target sites and exerting biological effects. Alternatively, the C-terminal miniproteins could interfere directly with endogenous wt p53 by oligomerizing with it and forming a complex which is deficient in sequence-specific DNA binding.
To distinguish between these two alternative mechanisms, we compared the DNA binding capacities of extracts from RMDD, RMDASS, and clone 51 (REF transformed by myc plus ras only). A short oligonucleotide, previously shown to bind specifically to wt p53 (40) , was labeled and incubated with portions of each cell extract normalized for total protein content. The resultant DNA-protein complexes were then precipitated with PAb421, which recognizes an epitope present in both endogenous p53 and the two C-terminal miniproteins.
As seen in Fig. 5 , the various extracts exhibited significant differences in their abilities to engage in sequence-specific DNA binding. Extracts of clone 6 cells, expressing the ts p53 and serving as a positive control for specificity, behaved as expected. Thus, when the cells were kept at 32°C, a temperature at which the ts p53 regains wt-like activities (47), very intense sequence-specific binding was obtained with the corresponding extracts. On the other hand, when the cells were grown at 37.5°C, at which most of the p53 molecules are in a mutant conformation, the specific binding to the DNA target was greatly reduced. It is noteworthy that clone 6 makes very high levels of transfected mouse p53 (54), which is reflected in the most prominent signal observed in Fig. 5 (29) ; C.6, clone 6 (see Fig. 3 (13) . The same element was also used in the experiment shown in Fig. 6 and 7 .
The results presented in Fig. 5 would suggest that the internally deleted miniprotein cannot interfere with sequence-specific DNA binding by coexpressed wt p53. However, the tendency of the RMDASS cells to lose the expression of the miniprotein caused the corresponding cell extracts to contain rather limited amounts of this peptide at the time of the assay (see Fig. 8B ). One could argue that these amounts were insufficient to bring about a substantial repression of DNA binding. To overcome this difficulty, we performed a similar set of experiments with in vitro-translated polypeptides. Plasmids encoding either the intact wt protein or each of the two miniproteins were transcribed in vitro (see Materials and Methods). The resultant RNA species were translated in a reticulocyte lysate in the presence of radiolabeled methionine. Half of each reaction mixture was then subjected to SDS-PAGE (Fig. 6B) , and the other half was used in a DNA binding assay (Fig. 6A) . As the radiolabeled target DNA, we used a 105-bp mouse genomic DNA fragment, isolated through a screening for p53 binding sequences (see above). In vitro-translated intact wt p53 exhibited very strong DNA binding (Fig. 6A, p53wt) . On the other hand, neither the DD miniprotein alone nor the DASS miniprotein could form detectable sequence-specific DNAprotein complexes (Fig. 6A) .
We next determined the effects of the DD and the DASS miniproteins on the sequence-specific DNA binding activity of cotranslated full-length wt p53. To obtain more quantitative results, a calibration series was performed with increasing amounts of wt p53 alone. Following densitometric scanning of the bands shown in Fig. 7A and B , the values were plotted as shown in Fig. 7C . Overall, when no additional miniproteins were present, the amount of radiolabeled target DNA brought down in the binding assay was proportionate to the amount of wt p53. When wt p53 was translated together with DASS, relatively low levels of the former were made, presumably owing to reduced translational efficiency. Nevertheless, the extent of DNA binding obtained with these relatively low levels of wt p53 was within the range expected for comparable amounts of free wt p53 (Fig. 7C; compare also lanes 1 and 7 in Fig. 7A and B) . Hence, the presence of DASS failed to exert any meaningful effect on the ability of cotranslated intact wt p53 to bind to its cognate DNA targets. On the other hand, a comparable excess of the DD polypeptide (see the legend to Fig. 7 ) caused a dramatic reduction in sequence-specific DNA binding by cotranslated wt p53. These results show unequivocally that the abrogation of specific DNA binding in RMDD cells (Fig. 5 ) must be directly due to the effect of the miniprotein on the intact endogenous p53. Moreover, the internal deletion present in the DASS miniprotein abolishes this inhibitory effect.
Taken together, the findings presented above strongly imply that the transforming activity of the DD miniprotein is due to its ability to extinguish the interaction between endogenous wt p53 and its cognate DNA targets. The failure of the DASS miniprotein to block DNA binding further suggests that this blocking probably relies on the oligomerization of the transforming C-terminal fragment with endogenous wt p53.
DD miniprotein stabilizes endogenous p53 in transformed cells. We next sought to assess the relative stabilities of the various miniproteins. To that end, the pulse-chase analysis depicted in Fig. 8A was performed. In the cells used in this experiment, DASS polypeptide levels were already relatively low, reflecting the gradual loss of expression during VOL. 12, 1992 that posttranslational modification may contribute to the stability of these miniproteins. The high-molecular-weight bands which appear at the DASS extracts represent nonspecific coprecipitation and are also brought down in the absence of p53 specific antibodies (14) . Unlike the similar stabilities of the DD and DASS polypeptides themselves, there were pronounced differences in the turnover rates of endogenous rat p53 between the corresponding cell lines. In RMDASS cells, the half-life of endogenous p53 was about 30 min. This is similar to the value described before for wt p53 in fibroblasts (51, 57) and also to that observed in clone 51 cells, which do not carry any transfected p53 (Fig. 6) . In contrast, cells expressing the DD miniprotein, which can complex with endogenous wt p53, exhibited a marked stabilization of the endogenous rat protein. Instead of 0.5 h, the half-life of this protein now became very similar to that of the DD miniprotein itself. Consequently, the steady-state levels of endogenous p53 were much higher in RMDD cells than in RMDASS cells (Fig. 8B) . These results indicate that formation of a complex between wt p53 and a relatively stable C-terminal p53 fragment leads to a major increase in the stability of the normally labile wt p53. DISCUSSION The results described in this study indicate that a region as short as 59 amino acid residues (positions 302 to 360 of mouse p53) is sufficient for the formation of stable p53 oligomers. Our findings confirm the previous assignment of the dimerization domain of p53 to its C-terminal region (36, 40) and localize it more precisely. Deletion of residues 330 to 344 abolished the ability of the corresponding polypeptide to oligomerize with full-length p53, indicating that residues within the deleted element are essential for, and presumably constitute part of, the dimerization domain. While this work was under review, Sturzbecher et al. (68) reported the detailed mapping of p53 domains involved in protein oligomerization. They found that the major element responsible for p53-p53 interactions spans residues 334 to 356 of human p53. The failure of the DASS miniprotein to engage in such interactions is consistent with these findings. Additionally, they also observed a requirement for basic residues located very close to the C terminus of p53 in order to convert dimers into homotetramers.
Remarkably, there appears to be a strict correlation between the efficacy with which a given C-terminal miniprotein oligomerizes with intact wt p53 in vitro and its transforming potential. This highly suggests that the transforming activity of these miniproteins is exerted through the formation of stable complexes with the endogenous wt p53 of transfected cells. It is noteworthy that there was no need for an additional point mutation to render these miniproteins transforming. In this sense, such wt p53-derived C-terminal fragments may be analogous to transforming p53 mutants. Thus, oligomerization with endogenous wt p53 may also be a major factor determining the transformation potency of full-length mutant p53, as assayed on REF. Yet, this is probably not the only factor, as indicated by the fact that certain tumor-derived p53 mutants transform more efficiently than others, even though they do not exhibit tighter interactions with endogenous cell p53 (29) .
Certain other features of p53 are clearly dispensable for transforming activity. Thus, retention of the serine at position 312 of murine p53, which serves as a phosphorylation target for a cyclin-dependent protein kinase (4, 69) (56, 70) . It still remains to be determined whether the latter will hold true also for cases in which mutant p53 acts in an apparently dominant positive mode, in the absence of any coexpressed wt p53 (6, 76) . Another aspect has to do with the subcellular localization of the transforming p53 molecules. Our studies clearly indicate that the bound wt p53 does not have to be excluded from the nucleus to render it nonfunctional. In fact, in some cases, nuclear localization has been shown to contribute to, rather than hinder, the transforming activity of mutant p53 (62, 65) . Hence, while it is still possible that certain transforming p53 mutants act by preventing bound wt p53 from entering the nucleus at some crucial stages of the cell cycle (44), this does not appear to be a universal mechanism for p53-mediated transformation. Rather, the common feature of all transforming p53 variants may be the direct abrogation of a biochemical property of wt p53. Our results suggest that this property may be the sequence-specific binding of wt p53
to DNA targets.
There is mounting evidence that sequence-specific DNA binding may be a hallmark of wt p53 (3, 13, 40) . It now appears most likely that inactivating p53 point mutations, of the types found in cancer cells, are primarily aimed at ablating the ability of the mutant protein to bind tightly and selectively to its cognate DNA targets. Similarly, any other mechanism that will prevent wt p53 from engaging in such DNA binding will also render it effectively nonfunctional. Our data suggest that one such mechanism may operate through the formation of DNA binding-incompetent mixed oligomers between mutant p53 and coexpressed wt p53, providing a rationale for the dominant negative effects of the former. Two additional recent studies also demonstrate that mutant p53 can inhibit the sequence-specific binding of wt p53 to cognate DNA targets (18, 39) .
The biochemical significance of the interaction between wt p53 and specific DNA targets is still unclear. It may be involved in transcriptional control. This will be consistent with the many indications that p53 can act as a transcriptional regulator (8, 19, 24, 46, 52, 55, 56, 60, 74) . Alternatively, the binding of p53 to specific DNA targets may be relevant for its putative involvement in the control of DNA replication, suggested on the basis of a variety of studies (5, 22, 38, 40, 72, 75) . If sequence-specific DNA binding is required for one or more of these activities of wt p53, it is conceivable that any mechanism that can interfere with this binding may alleviate the growth-restrictive effects of the protein and result in enhanced transformation and oncogenicity. Nevertheless, it should be stressed that the data presented here do not formally prove that the transforming activity of the miniproteins is achieved through a dominant negative mechanism. To that end, one will have to test these miniproteins in a system in which the antiproliferative potential of wt p53 can be directly monitored; such experiments are under way.
It is noteworthy that, under the experimental conditions used in this study, the DD miniprotein does not display any measurable sequence-specific DNA binding. Previous studies with calf thymus DNA have localized the DNA binding domain of p53 to its extreme C terminus (66) . In agreement with these observations, we also find that DD is capable of binding to immobilized double-stranded calf thymus DNA (data not shown). However, the last 89 residues of mouse p53 are apparently insufficient for effective sequence-specific DNA binding. Thus, as in many other DNA binding proteins (e.g., see reference 10), the structural requirements for sequence-specific DNA binding by p53 are not the same as for nonspecific binding.
Another interesting observation is that the abrogation of sequence-specific DNA binding correlates with a significant increase in the half-life of endogenous, presumably wt p53 (Fig. 6 ). This finding, along with earlier ones (27, 28, 34, 51, 58, 79) , further enforces the notion that loss of rapid degradation of wt p53 is coupled with its state of activity. When the wt activity of p53 is abrogated, either directly by mutations or indirectly through a dominant negative mechanism, the protein is somehow uncoupled from its normal degradative pathway and ends up accumulating in the cells.
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Finally, it should be stressed that while negative dominant effects of mutant p53 are easily demonstrable in artificial experimental systems, the extent to which they contribute to naturally occurring neoplastic processes is still an unresolved issue. Typically, one has to use a large excess of transfected mutant p53 over wt p53 to achieve rapid and efficient transformation in culture. In fact, in in vitro transfection assays, a 1:1 ratio between cotransfected mutant and wt p53 is insufficient to exert any measurable dominant negative effect of the former over the latter (6, 15, 20, 37 ). Yet, certain tumors have been found to coexpress one mutant p53 allele along with one which is still wt (7, 11, 30) , even though this is not a very frequent situation, and tumors with a mutant allele often tend to lose the other one or have it undergo an independent second mutation. We therefore suggest that cells coexpressing comparable amounts of wt and mutant p53 experience only a modest reduction in total levels of wt p53 activity. A reduction of this scope will be too mild to affect rapid phenotypic changes that can be scored in short-term tissue culture assays. However, in the much slower process of in vivo tumor progression, it may already confer the cells with a limited growth advantage, which will then increase the probability of a second genetic hit disposing of the remaining wt p53 allele. By the time these cells present as a distinct tumor, they will therefore often already be devoid of any wt p53 expression.
